ID

25909

Descrição

A Long-term Administration Study of OPC-41061 in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) (2) [Extension of Study 156-05-002]; ODM derived from: https://clinicaltrials.gov/show/NCT01022424

Link

https://clinicaltrials.gov/show/NCT01022424

Palavras-chave

  1. 26/09/2017 26/09/2017 -
Transferido a

26 de setembro de 2017

DOI

Para um pedido faça login.

Licença

Creative Commons BY 4.0

Comentários do modelo :

Aqui pode comentar o modelo. Pode comentá-lo especificamente através dos balões de texto nos grupos de itens e itens.

Comentários do grupo de itens para :

Comentários do item para :

Para descarregar formulários, precisa de ter uma sessão iniciada. Por favor faça login ou registe-se gratuitamente.

Eligibility Autosomal Dominant Polycystic Kidney Disease NCT01022424

Eligibility Autosomal Dominant Polycystic Kidney Disease NCT01022424

Inclusion Criteria
Descrição

Inclusion Criteria

Alias
UMLS CUI
C1512693
patients who completed 3-year repeated administrations and the follow-up observation or those who were withdrawn from the study due to reasons other than occurrence of adverse events (based on the judgment of either the subject or the investigator/subinvestigator) in the preceding study (156-05-002)
Descrição

Study Subject Participation Status | Protocol Compliance | Patient withdrawn from trial

Tipo de dados

boolean

Alias
UMLS CUI [1]
C2348568
UMLS CUI [2]
C0525058
UMLS CUI [3]
C0422727
patients in whom adverse events occurring in study 156-05-002 were resolved or became stable and do not require further follow-up.
Descrição

Study Subject Participation Status | Adverse events resolved | Adverse events Stable

Tipo de dados

boolean

Alias
UMLS CUI [1]
C2348568
UMLS CUI [2,1]
C0877248
UMLS CUI [2,2]
C1514893
UMLS CUI [3,1]
C0877248
UMLS CUI [3,2]
C0205360
Exclusion Criteria
Descrição

Exclusion Criteria

Alias
UMLS CUI
C0680251
patients with egfr of less than 15 ml/min/1.73 m2
Descrição

Estimated Glomerular Filtration Rate

Tipo de dados

boolean

Alias
UMLS CUI [1]
C3811844
patients with any of the following complications:
Descrição

Complications

Tipo de dados

boolean

Alias
UMLS CUI [1]
C0009566
uncontrolled hypertension
Descrição

Uncontrolled hypertension

Tipo de dados

boolean

Alias
UMLS CUI [1]
C1868885
serious cardiovascular disease (eg. heart failure) or hepatic disease (eg. cirrhosis)
Descrição

Cardiovascular Diseases Serious | Heart failure | Liver diseases | Liver Cirrhosis

Tipo de dados

boolean

Alias
UMLS CUI [1,1]
C0007222
UMLS CUI [1,2]
C0205404
UMLS CUI [2]
C0018801
UMLS CUI [3]
C0023895
UMLS CUI [4]
C0023890
patients with any of the following complications or history thereof:
Descrição

Complications

Tipo de dados

boolean

Alias
UMLS CUI [1]
C0009566
clinically significant drug allergies (anaphylaxis) or hypersensitivity (especially, hypersensitivity to benzazepine derivatives or suspected hypersensitivity
Descrição

Drug Allergy | Drug related anaphylaxis | Hypersensitivity Benzazepine derivatives | Hypersensitivity Suspected Benzazepine derivatives

Tipo de dados

boolean

Alias
UMLS CUI [1]
C0013182
UMLS CUI [2]
C0850607
UMLS CUI [3,1]
C0020517
UMLS CUI [3,2]
C0005034
UMLS CUI [3,3]
C0243072
UMLS CUI [4,1]
C0020517
UMLS CUI [4,2]
C0750491
UMLS CUI [4,3]
C0005034
UMLS CUI [4,4]
C0243072
inability to personally give consent due to a mental illness
Descrição

Mental disorders Informed Consent Unable

Tipo de dados

boolean

Alias
UMLS CUI [1,1]
C0004936
UMLS CUI [1,2]
C0021430
UMLS CUI [1,3]
C1299582

Similar models

Eligibility Autosomal Dominant Polycystic Kidney Disease NCT01022424

Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de dados
Alias
Item Group
C1512693 (UMLS CUI)
Study Subject Participation Status | Protocol Compliance | Patient withdrawn from trial
Item
patients who completed 3-year repeated administrations and the follow-up observation or those who were withdrawn from the study due to reasons other than occurrence of adverse events (based on the judgment of either the subject or the investigator/subinvestigator) in the preceding study (156-05-002)
boolean
C2348568 (UMLS CUI [1])
C0525058 (UMLS CUI [2])
C0422727 (UMLS CUI [3])
Study Subject Participation Status | Adverse events resolved | Adverse events Stable
Item
patients in whom adverse events occurring in study 156-05-002 were resolved or became stable and do not require further follow-up.
boolean
C2348568 (UMLS CUI [1])
C0877248 (UMLS CUI [2,1])
C1514893 (UMLS CUI [2,2])
C0877248 (UMLS CUI [3,1])
C0205360 (UMLS CUI [3,2])
Item Group
C0680251 (UMLS CUI)
Estimated Glomerular Filtration Rate
Item
patients with egfr of less than 15 ml/min/1.73 m2
boolean
C3811844 (UMLS CUI [1])
Complications
Item
patients with any of the following complications:
boolean
C0009566 (UMLS CUI [1])
Uncontrolled hypertension
Item
uncontrolled hypertension
boolean
C1868885 (UMLS CUI [1])
Cardiovascular Diseases Serious | Heart failure | Liver diseases | Liver Cirrhosis
Item
serious cardiovascular disease (eg. heart failure) or hepatic disease (eg. cirrhosis)
boolean
C0007222 (UMLS CUI [1,1])
C0205404 (UMLS CUI [1,2])
C0018801 (UMLS CUI [2])
C0023895 (UMLS CUI [3])
C0023890 (UMLS CUI [4])
Complications
Item
patients with any of the following complications or history thereof:
boolean
C0009566 (UMLS CUI [1])
Drug Allergy | Drug related anaphylaxis | Hypersensitivity Benzazepine derivatives | Hypersensitivity Suspected Benzazepine derivatives
Item
clinically significant drug allergies (anaphylaxis) or hypersensitivity (especially, hypersensitivity to benzazepine derivatives or suspected hypersensitivity
boolean
C0013182 (UMLS CUI [1])
C0850607 (UMLS CUI [2])
C0020517 (UMLS CUI [3,1])
C0005034 (UMLS CUI [3,2])
C0243072 (UMLS CUI [3,3])
C0020517 (UMLS CUI [4,1])
C0750491 (UMLS CUI [4,2])
C0005034 (UMLS CUI [4,3])
C0243072 (UMLS CUI [4,4])
Mental disorders Informed Consent Unable
Item
inability to personally give consent due to a mental illness
boolean
C0004936 (UMLS CUI [1,1])
C0021430 (UMLS CUI [1,2])
C1299582 (UMLS CUI [1,3])

Use este formulário para feedback, perguntas e sugestões de aperfeiçoamento.

Campos marcados com * são obrigatórios.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial